FSN Capital buys Prange Group’s remaining stake in Adragos Pharma

FSN Capital VI acquired Prange Group’s remaining shares in Adragos Pharma, taking full control alongside management. Prange Group exited its entire stake following a 2021 partnership that backed the CDMO’s expansion across Europe and Japan. Financial terms were not disclosed.